期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 569, 期 -, 页码 79-85出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2021.06.088
关键词
Ferroptosis; Cisplatin; PRLX93936; Non-small cell lung cancer; GPX4; Nrf2/Keap1
资金
- Fund of Zhejiang Provincial Key Laboratory of Advanced Mass Spectrometry Technology [AMSMAKF2102]
Synergistic induction of ferroptosis by cisplatin and PRLX93936 is a promising new therapeutic strategy for non-small cell lung cancer (NSCLC), involving upregulation of ROS, lipid peroxidation, Fe2+, inhibition of GPX4, and modulation of the Nrf2/Keap1 pathway.
Ferroptosis is a newly identified type of regulated cell death that is affected by lipid peroxidation and reactive oxygen species (ROS). In the current study, we showed that cisplatin and PRLX93936, an analog of erastin that has been tested in clinical trials, demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells. Cotreatment with cisplatin and PRLX93936 induced ferroptosis, as evidenced by the upregulation of ROS, lipid peroxidation and Fe2+. Further investigation revealed that cotreatment with cisplatin and PRLX93936 inhibited GPX4 and that overexpression of GPX4 prevented cell death. Moreover, the Nrf2/Keap1 pathway also regulated the sensitivity to cisplatin and PRLX93936 in NSCLC cells. Nrf2 silencing increased this sensitivity while inhibition of Keap1 attenuated it. Overall, our data reveal a new effective treatment for NSCLC by synergizing cisplatin and PRLX93936 to induce ferroptosis. (c) 2021 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据